Author: Fiona Craig

Blue Star Capital plc (LSE:BLU) has revealed that its portfolio company, SatoshiPay, has fully deployed a £1 million loan to broaden its digital asset holdings by acquiring Ether and Coinbase Wrapped Bitcoin (WBTC). This strategic move is designed to strengthen SatoshiPay’s treasury management and improve liquidity for its Vortex project, leveraging decentralized finance (DeFi) technologies. The investment underscores Blue Star Capital’s commitment to advancing blockchain-based innovations.

About Blue Star Capital

Blue Star Capital plc specializes in investments across emerging technology sectors, including blockchain, payments, and esports. Its key holdings include SatoshiPay Ltd, a pioneer in blockchain payment solutions; Dynasty Media & Gaming, which offers a B2B white-label gaming platform; and Paidia, a gaming platform focused on women.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

GlaxoSmithKline plc (LSE:GSK) has finalized a settlement with CureVac and BioNTech concerning ongoing mRNA patent litigation. Under the agreement, GSK will receive an upfront payment of $370 million, plus a 1% royalty on future US sales of mRNA vaccines produced by Pfizer and BioNTech. The settlement, which will be reflected in GSK’s financial statements, does not impact the company’s continued patent enforcement actions against Pfizer and BioNTech in both the US and Europe. The deal also includes a tender offer related to GSK’s holdings in CureVac shares.

GSK Outlook

GlaxoSmithKline maintains a strong financial position supported by strategic moves such as share repurchases and acquisitions aimed at boosting shareholder returns. Market sentiment appears neutral based on technical indicators, while valuation remains balanced with a compelling dividend yield. The company’s earnings call emphasized growth prospects in specialty medicines, although vaccine sales and regulatory factors continue to pose challenges.

About GlaxoSmithKline

GSK is a leading global biopharmaceutical firm dedicated to advancing healthcare through innovation in science, technology, and talent to address serious diseases worldwide.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Flutter Entertainment PLC (LSE:FLTR) delivered impressive results for the second quarter of 2025, with revenues climbing 16% and adjusted EBITDA up 25%, fueled by strong growth across the US and international markets. Although net income fell sharply by 88% due to non-cash charges, the company raised its full-year guidance, underscoring confidence in its strategic direction. Key drivers include the recent acquisitions of Snai and NSX, alongside a bolstered presence in the US. Flutter also highlighted ongoing regulatory challenges, especially in Illinois, but reaffirmed its commitment to leveraging its scale and market leadership to adapt to tax changes and sustain its competitive position.

About Flutter Entertainment PLC

Flutter Entertainment PLC is a global leader in online sports betting and iGaming, operating major brands such as FanDuel and Betfair. The company pursues growth through both strategic acquisitions and organic expansion, focusing on markets including the US, UK, Ireland, Southern Europe, Africa, and the Asia-Pacific region.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Premier African Minerals Limited (LSE:PREM) has made headway in the second phase of plant testing at its Zulu Lithium and Tantalum Project. The company is tackling optimization and commissioning challenges, showing encouraging outcomes so far. A decision on acquiring a secondary spodumene flotation section is anticipated soon. Meanwhile, longer-term plans are underway to address plant issues, including replacing the initial sorters and completing the tantalum recovery circuit, which has attracted interest from potential buyers.

About Premier African Minerals

Premier African Minerals Limited is a diversified mining and natural resource development firm focused on Southern Africa. Its portfolio includes operations and exploration in Zimbabwe and Mozambique across several commodities such as tungsten, rare earth elements, lithium, tantalum, and gold, combining both brownfield assets and early-stage projects.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Stelrad Group plc (LSE:SRAD) released its interim results for the first half of 2025, demonstrating resilient financial performance amid a challenging market landscape. The company upheld its leadership position in the European steel panel radiator market, securing a 19.9% share outside Russia, where it commands 25.4%. Adjusted operating profit edged up by 1.1% to £15.9 million, supported by effective margin controls and favorable currency movements. However, revenue fell 4.6%, reflecting softer demand in key regions. Despite these hurdles, Stelrad increased its interim dividend by 2% and remains optimistic about its long-term growth potential.

Stelrad Group’s outlook is buoyed by strong financial fundamentals, positive technical signals, and reasonable valuation. While profitability and cash flow remain solid, the company faces risks from high leverage levels and technical indicators nearing overbought status.

About Stelrad Group Plc

Stelrad Group plc is a prominent European manufacturer of specialist radiators, offering a broad portfolio that includes hydronic, hybrid, dual fuel, and electric heating solutions. The group operates in over 40 countries with key brands such as Stelrad, Henrad, Termo Teknik, DL Radiators, and Hudevad. Headquartered in Newcastle upon Tyne, UK, Stelrad maintains manufacturing and distribution centers across Turkey, the UK, Italy, and the Netherlands.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Keras Resources plc (LSE:KRS) reports notable developments in its mining activities. Its Falcon Isle subsidiary in Utah is actively producing Phosul® granulate along with dry rock phosphate products, with plans to boost phosphate stockpiles by 5,000 tons ahead of increased winter demand. Concurrently, the Nayéga manganese mine in Togo has finished recommissioning and is now scaling up its output, with intentions to expand processing capabilities. These operational improvements are expected to generate positive cash flow, strengthening Keras Resources’ presence in both the organic and conventional fertilizer markets.

About Keras Resources

Keras Resources plc is an AIM-listed mining company focused on producing high-quality organic phosphate products, primarily via its Diamond Creek mine in Utah, USA. The company operates an integrated mine-to-market system serving the organic fertilizer industry. Additionally, Keras manages the Nayéga manganese mine in Togo, aiming to grow its footprint within the US organic fertilizer sector.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Panther Metals Plc (LSE:PALM) has initiated comprehensive studies to assess and quantify the valuable gold and critical minerals present in the historic tailings at the Winston Lake Mine in Ontario, Canada. The company is progressing through historical data reviews, technical evaluations, and regulatory permitting to accelerate the reprocessing of these tailings. This initiative aims to boost cash flow while supporting environmental restoration efforts. Recent changes to Ontario’s regulatory framework are expected to simplify the permitting process, enabling quicker mineral recovery operations.

About Panther Metals Plc

Panther Metals Plc is a mineral exploration company operating primarily in Canada. Its focus lies in evaluating and reprocessing mineral deposits, targeting high-grade resources such as gold, silver, zinc, copper, and cobalt. The company specializes in extracting residual value from historic mine tailings to unlock additional metal resources.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Pennant International Group plc (LSE:PEN) has issued a trading update for the first half of 2025, reporting revenues of £4.5 million, down from the previous year. The company is experiencing delays with its GenFly technology upgrade contract awarded by the Ministry of Defence, impacting anticipated revenue for the year. Despite this, Pennant is emphasizing growth in its Auxilium software platform, which has seen an increase in annual recurring revenue. Efforts are underway to expand sales channels and onboard new distribution partners to support the company’s software and services growth plans.

Pennant’s outlook is challenged by weak financial results and valuation concerns, highlighted by ongoing losses and negative cash flow. However, recent corporate developments and improving technical signals provide some optimism. Strategic collaborations and effective asset management could enhance the company’s future growth trajectory.

About Pennant International

Pennant International Group plc is a technology-focused global provider offering system support software, technical services, and training solutions. It serves critical sectors such as Aerospace, Defence, and Rail, along with related fields like Shipping, Nuclear, and Space. The company targets sustainable, repeatable revenue growth, particularly through high-margin software and services, benefiting from rising defence spending and increasing complexity in military, aviation, and rail technologies.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

RC365 Holding plc (LSE:RCGH) has responded to recent investor speculation by confirming that its asset-backed card offering continues to support digital assets such as stablecoins within its current business framework. The company stressed that this approach does not signal any change in strategic direction and remains fully compliant with applicable regulatory standards across its operating regions. RC365 reaffirmed its commitment to transparent communication and promised to keep stakeholders informed with updates as appropriate.

The company’s outlook is challenged by ongoing financial and technical hurdles. Despite showing growth in revenue, profitability remains a concern, compounded by high leverage. Technical analysis points to a bearish momentum, and valuation indicators suggest the stock may be overvalued.

About RC365 Holding PLC

RC365 Holding plc is a fintech and payment solutions provider with a strong presence in East and Southeast Asia through its subsidiaries, Regal Crown Technology and HC Capital. The company offers secure payment gateway services, IT support, and development for financial systems, including ERP platforms. Since 2021, RC365 has broadened its portfolio to include digital remittance, foreign exchange, and asset-backed credit card products, catering to multinational businesses, SMEs, and individual customers. The company has ambitions to expand into virtual banking and enter new markets in the UK and Europe.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Futura Medical plc (LSE:FUM) has appointed Alex Duggan as interim CEO following recent board changes, including the departure of Angela Hildreth, who stepped down as Finance Director and COO. Duggan brings extensive leadership expertise and will oversee a strategic review focused on the company’s sales and marketing approach for its flagship product, Eroxon, which has experienced slower-than-anticipated sales growth. This review aims to sharpen commercial strategies and enhance stakeholder value, with an update anticipated by late September.

About Futura Medical

Futura Medical plc specializes in developing innovative sexual health treatments, primarily focusing on topical gel formulations. Its leading product, Eroxon, is a clinically validated topical gel designed to treat Erectile Dysfunction (ED), providing a unique over-the-counter option that acts within ten minutes. The company has secured distribution partnerships across key markets, including the US and Europe, targeting significant unmet demand in the ED segment.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.